Cipla Sounds The Bugle On US Respiratory Ambition

One "sizeable" respiratory inhalation launch in the US every year, starting next year, is what Cipla is targeting as it expands its global franchise in the segment, though a filing this year for generic Advair isn't likely. The Indian firm also expects to sew up multiple biosimilar deals targeted at key emerging markets.

Success ladder leading to cloud and many short ones. Business, goal, competition, unique, progress, challenge, hope and leadership concept. EPS 8 vector illustration, no transparency
CIPLA IS AIMING FOR A BIGGER PLAY IN THE US RESPIRATORY SEGMENT

Cipla Ltd., which has been expanding its respiratory franchise globally, has indicated that it is revving up in the segment in the US, a market where the Indian firm has traditionally derived a smaller proportion of its overall revenues compared with some large Indian peers.

The Indian company may be lagging some frontliners for a generic Advair (fluticasone/salmeterol) in the US but management commentary provided...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

More from Scrip

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.